Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025
Applied DNA Sciences (NASDAQ:APDN) has announced a 1-for-50 reverse stock split effective March 14, 2025. The split will reduce outstanding shares from approximately 55.2 million to 1.1 million, while maintaining trading on the Nasdaq Capital Market under the same symbol 'APDN'.
The reverse split follows stockholder approval granted on September 30, 2024, authorizing the Board to implement a split ratio between 1-for-5 and 1-for-50. The Board approved the maximum ratio on March 3, 2025, aiming to comply with Nasdaq's $1.00 minimum bid price requirement for continued listing.
The company will adjust proportionally all outstanding stock options, restricted stock units, and warrants. Fractional shares will be rounded up to the nearest whole share, and the $0.001 par value per share will remain unchanged.
Applied DNA Sciences (NASDAQ:APDN) ha annunciato un raggruppamento azionario inverso 1-per-50 che entrerà in vigore il 14 marzo 2025. Questo raggruppamento ridurrà le azioni in circolazione da circa 55,2 milioni a 1,1 milioni, mantenendo il trading sul Nasdaq Capital Market con lo stesso simbolo 'APDN'.
Il raggruppamento inverso segue l'approvazione degli azionisti concessa il 30 settembre 2024, che autorizza il Consiglio a implementare un rapporto di raggruppamento compreso tra 1-per-5 e 1-per-50. Il Consiglio ha approvato il rapporto massimo il 3 marzo 2025, con l'obiettivo di rispettare il requisito di prezzo minimo di offerta di $1,00 per il mantenimento della quotazione su Nasdaq.
L'azienda regolerà proporzionalmente tutte le opzioni azionarie in circolazione, le unità azionarie vincolate e i warrant. Le azioni frazionarie saranno arrotondate all'azione intera più vicina e il valore nominale di $0,001 per azione rimarrà invariato.
Applied DNA Sciences (NASDAQ:APDN) ha anunciado un split inverso de acciones 1 por 50 que entrará en vigor el 14 de marzo de 2025. Este split reducirá las acciones en circulación de aproximadamente 55,2 millones a 1,1 millones, manteniendo el comercio en el Nasdaq Capital Market bajo el mismo símbolo 'APDN'.
El split inverso sigue a la aprobación de los accionistas concedida el 30 de septiembre de 2024, que autoriza a la Junta a implementar una relación de split entre 1 por 5 y 1 por 50. La Junta aprobó la relación máxima el 3 de marzo de 2025, con el objetivo de cumplir con el requisito de precio mínimo de oferta de $1.00 para mantener la cotización.
La empresa ajustará proporcionalmente todas las opciones de acciones en circulación, las unidades de acciones restringidas y los warrants. Las acciones fraccionarias se redondearán a la acción entera más cercana, y el valor nominal de $0.001 por acción permanecerá sin cambios.
Applied DNA Sciences (NASDAQ:APDN)는 1대 50 비율의 주식 병합을 2025년 3월 14일부터 시행한다고 발표했습니다. 이번 병합으로 발행 주식 수는 약 5,520만 주에서 110만 주로 줄어들며, 'APDN'이라는 동일한 기호로 Nasdaq 자본 시장에서 거래가 유지됩니다.
이번 비율 병합은 2024년 9월 30일 주주 승인 후 이루어지며, 이 승인으로 이사회는 1대 5에서 1대 50 사이의 비율을 시행할 수 있게 되었습니다. 이사회는 2025년 3월 3일 최대 비율을 승인하였으며, 이는 Nasdaq의 $1.00 최소 입찰 가격 요건을 충족하기 위한 것입니다.
회사는 모든 발행 주식 옵션, 제한 주식 단위 및 워런트를 비례적으로 조정할 것입니다. 분할 주식은 가장 가까운 정수 주식으로 반올림되며, 주당 $0.001의 액면가는 변경되지 않습니다.
Applied DNA Sciences (NASDAQ:APDN) a annoncé un rachat d'actions inversé 1 pour 50 effectif le 14 mars 2025. Ce rachat réduira le nombre d'actions en circulation d'environ 55,2 millions à 1,1 million, tout en maintenant le commerce sur le Nasdaq Capital Market sous le même symbole 'APDN'.
Le rachat inversé fait suite à l'approbation des actionnaires accordée le 30 septembre 2024, autorisant le Conseil à mettre en œuvre un ratio de rachat compris entre 1 pour 5 et 1 pour 50. Le Conseil a approuvé le ratio maximum le 3 mars 2025, visant à respecter l'exigence de prix de soumission minimum de $1,00 pour le maintien de la cotation.
L'entreprise ajustera proportionnellement toutes les options d'actions en circulation, les unités d'actions restreintes et les bons de souscription. Les actions fractionnaires seront arrondies à l'action entière la plus proche, et la valeur nominale de $0,001 par action restera inchangée.
Applied DNA Sciences (NASDAQ:APDN) hat einen 1-zu-50 Rückwärtssplit angekündigt, der am 14. März 2025 in Kraft tritt. Der Split wird die ausstehenden Aktien von etwa 55,2 Millionen auf 1,1 Millionen reduzieren, während der Handel an der Nasdaq Capital Market unter demselben Symbol 'APDN' fortgesetzt wird.
Der Rückwärtssplit folgt der Genehmigung durch die Aktionäre, die am 30. September 2024 erteilt wurde, und autorisiert den Vorstand, ein Splitverhältnis zwischen 1-zu-5 und 1-zu-50 umzusetzen. Der Vorstand genehmigte das maximale Verhältnis am 3. März 2025, um die $1,00 Mindestgebotsanforderung von Nasdaq für die Fortführung der Notierung zu erfüllen.
Das Unternehmen wird alle ausstehenden Aktienoptionen, beschränkten Aktieneinheiten und Warrants proportional anpassen. Bruchstücke von Aktien werden auf die nächste ganze Aktie aufgerundet, und der Nennwert von $0,001 pro Aktie bleibt unverändert.
- Potential compliance with Nasdaq listing requirements
- Stockholder-approved corporate action
- No change in trading venue or symbol
- Indicates struggle to maintain minimum share price requirements
- Significant share consolidation (50:1 ratio) may signal financial distress
- No reduction in authorized shares, leaving potential for future dilution
Insights
Applied DNA Sciences has announced a 1-for-50 reverse stock split effective March 14, 2025, a strategic move to regain compliance with Nasdaq's minimum bid price requirement of
The mechanics of the split are straightforward: the outstanding share count will decrease from approximately 55.2 million to 1.1 million shares, while the current
Financial Analyst: The 1:50 ratio is particularly aggressive compared to typical reverse splits (often 1:10 or 1:20), suggesting an urgent need to boost share price significantly. While reverse splits technically preserve proportional ownership value, they often carry negative market perception. Historical market data shows that many companies implementing high-ratio reverse splits experience continued price declines afterward since the action doesn't address fundamental business challenges. With APDN's micro-cap status (
Corporate Governance Expert: This maneuver appears primarily designed as a compliance mechanism rather than reflecting business improvement. The board's decision to implement the maximum authorized ratio (1:50) from their previously approved range (1:5 to 1:50) indicates significant concern about maintaining Nasdaq listing. While this administrative action preserves the listing in the short term, investors should recognize that reverse splits of this magnitude typically occur in companies facing prolonged operational challenges. The structural adjustment doesn't create new value or improve the company's competitive position in the PCR-based DNA technologies market.
STONY BROOK, NY / ACCESS Newswire / March 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-50 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on Friday, March 14, 2025, and Applied DNA common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market as of the commencement of market open that same day.
Applied DNA common stock will continue to trade on The Nasdaq Capital Market under the symbol "APDN" following the reverse stock split, with a new CUSIP number of 03815U 508. The CUSIP number for the Company's book entry warrants will not change.
After the effectiveness of the reverse stock split, the number of outstanding shares of common stock will be reduced from approximately 55.2 million to approximately 1.1 million. The total authorized number of shares will not be reduced. Proportional adjustments will be made to the number of shares of common stock issuable upon exercise or vesting of the Company's outstanding stock options, restricted stock units, and warrants, as well as the applicable exercise or conversion prices, and to the number of shares issuable under the Company's equity incentive plans and other existing agreements. No fractional shares will be issued in connection with the reverse stock split, and fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share. There will be no change in the par value of
As previously disclosed, at an annual meeting of stockholders held on September 30, 2024, the Company's stockholders voted to approve a proposal granting the Company's Board of Directors the discretion to amend the Company's certificate of incorporation to effect a reverse stock split of the Company's common stock at a ratio of not less than 1-for-5 and not more than 1-for-50. The Company's Board of Directors approved a 1-for-50 reverse stock split on March 3, 2025. The reverse stock split is intended to bring the Company into compliance with Nasdaq's
Applied DNA's transfer agent, Equiniti Trust Company, will provide information to stockholders regarding their stock ownership following the reverse stock split. Stockholders holding their shares in book-entry form or through a bank, broker, or other nominee do not need to take any action in connection with the reverse stock split. Their accounts will be automatically adjusted to reflect the number of shares owned. Beneficial holders are encouraged to contact their bank, broker, or other nominee with any procedural questions.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA. The Company operates in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services.
Visit adnas.com for more information. Follow us on X and LinkedIn.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company's expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including statements regarding the effective date of the reverse stock split and the trading of the common stock on a split-adjusted basis, the Company's belief that the reverse stock split will allow the Company to regain compliance with Nasdaq listing standards, the Company's belief that restructuring will position the company for future growth potential, its goal to position the company for long term-growth and value creation, and the potential to achieve that goal, and regarding the future success of its Linea DNA™ and Linea™ IVT platforms and future reductions in operating expenses. Actual results could differ materially from those projected due to the Company's history of net losses, limited financial resources, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from our Linea IVT and or Linea DNA platforms, the fact that there has never been clinical trial material and/or a commercial drug product produced utilizing the LineaDNA and/or Linea IVT platforms, the unknown amount of revenues and profits that will result from its TR8™ PGx testing service, as well as various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, its Quarterly Report on Form 10-Q filed on February 13, 2025, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
Applied DNA Sciences Contact:
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Web: adnas.com
###
SOURCE: Applied DNA Sciences, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Applied DNA's (APDN) 1-for-50 reverse stock split take effect?
How many shares will APDN have outstanding after the reverse split?
Why is Applied DNA Sciences implementing this reverse stock split?
What happens to APDN shareholders' fractional shares after the split?
Will APDN's stock symbol or trading venue change after the reverse split?
